Benoît ROUSSEAU
机构: GI oncology Service, Diaz' Lab, Memorial Sloan Kettering Cancer Center
主页: researchgate.net
每年引用次数
引用次数
引用: 4,336
H-指数: 30
I10-指数 : 50
出版物: 151
Metastatic colorectal cancer (mCRC): French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR).
Jean Marc Phelip , David Tougeron , David Léonard , Leonor Benhaim
Digestive and Liver Disease 51 ( 10) 1357 -1363
81
2019
Mécanismes de résistances aux inhibiteurs de RAF : revue de la littérature
B. Rousseau pour l’Aerio
Oncologie 14 ( 1) 2 -4
2
2012
526O High activity of nivolumab in patients with pathogenic exonucleasic domain POLE (edPOLE) mutated Mismatch Repair proficient (MMRp) advanced tumours
B.J-C. Rousseau , I. Bieche , E. Pasmant , V. Simmet
Annals of Oncology 31
2020
Clinico-Biological Characteristics of Patients Surviving More Than Two Years with Recurrent and/or Metastatic (R/M) Cancer: Results of a Transversal National Multicentric Survey
D. Loirat , C. Tlemsani , F. Legouté , C. Renaudin-Fonsegrive
Annals of Oncology 25 iv484
2014
Predicting response to immune checkpoint blockade therapy among mismatch repair-deficient patients using mutational signatures
Doga C Gulhan , Vinay Viswanadham , Francesc Muyas , Hu Jin
medRxiv 2024.01. 19.24301236 -2024.01. 19.24301236
1
2024
Mechanisms of resistance to RAF inhibitors: literature review
B Rousseau pour l’Aerio
Oncologie 14 2 -4
1
2012
IMMUNOGENICITY AND SAFETY OF TWO DOSES OF AS03A-ADJUVANTED INFLUENZA A H1N1V 2009 VACCINE IN CANCER PATIENTS ON CHEMOTHERAPY-VACANCE STUDY
BJ Rousseau , P Loulergue , O Mir , E Viel
ANNALS OF ONCOLOGY 21 399 -400
2010
A phase I trial assessing the maximum tolerated dose (MTD) and pharmacokinetics of intrapleural bevacizumab after pleural puncture in breast cancer patients with symptomatic recurrent metastatic pleural effusion: The BEVAP trial.
Maya Gutierrez , Fawzia Mefti , Etienne Brain , Anne Hulin
Journal of Clinical Oncology 33
2015
Interleukin-17 mediates liver progenitor cell transformation into cancer stem cells through downregulation of miR-122
Imène Gasmi , Camilia Machou , Aurélie Rodrigues , Julien Calderaro
Cancer biology and medicine 15 14
2018
CD4 T cell dependent rejection of beta 2 microglobulin null mismatch repair deficient tumors.
Giovanni Germano , Steve Lu , Giuseppe Rospo , Simona Lamba
Cancer Discovery
1
2021
The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors.
Andrea Cercek , Steven B. Maron , Luis A. Diaz , Michael B. Foote
The New England Journal of Medicine 384 ( 12) 1168 -1170
98
2021
Development and validation of a prognostic nomogram and score to predict overall survival and usefulness of second-line chemotherapy in advanced pancreatic adenocarcinoma.
Angélique Vienot , Guillaume Beinse , Christophe Louvet , Louis de Mestier
Journal of Clinical Oncology 35 354 -354
1
2017
Multimodal treatment choice and feasibility in older patients with resectable gastric cancer: a multicentric cohort study.
Helene Boussion , Florence Canoui-Poitrine , Philippe Caillet , Christophe Louvet
Journal of Clinical Oncology 34
2016
RECIST and CHOI criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter study.
Romain Cohen , Marie-Line Garcia-Larnicol , Aurelien Gobert , Julie Henriques
Cancer Imaging 19 ( 1) 85
1
2019
Clinical criteria predicting an overall survival benefit to platinum rechallenge (PR) in metastatic urothelial cancer (mUC).
Elodie Mussat , Anne Jouinot , Carolina Saldana , Charlotte Joly
Journal of Clinical Oncology 38 ( 6_suppl) 490 -490
2020
Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group
Marine Sroussi , Reza Elaidi , Aude Fléchon , Marianne Lorcet
Clinical Genitourinary Cancer 18 ( 4)
3
2020
Acquired Type II von Willebrand Syndrome in Locally Advanced Bladder Cancer Successfully Treated With Intravenous Immunoglobulin and Chemotherapy.
Guillaume Dumas , Benoit Rousseau , Manuel Jorge Rodrigues , Camille Tlemsani
Clinical Genitourinary Cancer 14 ( 1)
2016
Prediction of overall survival with 2nd-line (L2OS) chemotherapy (CT) in patients (Pts) with advanced biliary tract cancer (aBTC): AGEO CT2BIL cohort update and international multicenter external validations.
Cindy Neuzillet , Andrea Casadei Gardini , Bertrand Brieau , Caterina Vivaldi
Journal of Clinical Oncology 36 ( 15_suppl) e16119 -e16119
2018
PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma.
Jacqueline Fontugne , Jérémy Augustin , Anaïs Pujals , Philippe Compagnon
Oncotarget 8 ( 15) 24644 -24651
78
2017
Characteristics of BRAFV600E Mutant, Deficient Mismatch Repair/Proficient Mismatch Repair, Metastatic Colorectal Cancer: A Multicenter Series of 287 Patients
Christelle Fouchardière , Romain Cohen , David Malka , Rosine Guimbaud
Oncologist 24 ( 12)
7
2019